Claims
- 42. A method for the expression of a heterologous polypeptide by a host cell said method comprising:
a) introducing into a host cell a chimeric nucleic acid sequence comprising:
1) a first nucleic acid sequence capable of regulating the transcription in said host cell of 2) a second nucleic acid sequence, wherein said second sequence encodes a fusion polypeptide and comprises (i) a nucleic acid sequence encoding a sufficient portion of an oil body protein gene to provide targeting of the fusion polypeptide to a lipid phase linked in reading frame to (ii) a nucleic acid sequence encoding the heterologous polypeptide; and 3) a third nucleic acid sequence encoding a termination region functional in the host cell; and b) growing said host cell to produce the fusion polypeptide.
- 43. The method according to claim 42 further including separating the recombinant fusion polypeptide from cellular host cell components by selective partitioning into a lipid phase.
- 44. The method according to claim 43 wherein said selective partitioning comprises centrifugation, floatation or size exclusion.
- 45. The method according to claim 42 further including separating the recombinant fusion polypeptide from cellular host components by selective partitioning into a lipid phase comprising oil bodies.
- 46. The method according to claim 45 wherein said recombinant fusion polypeptide is separated by addition of oil body components and reconstitution of the oil bodies.
- 47. The method according to claim 43 further comprising releasing the heterologous polypeptide from the fusion polypeptide associated with the lipid phase, said method comprising:
c) including in said second nucleic acid sequence (2) between said nucleic acid sequence (i) encoding the oil body protein and the nucleic acid sequence (ii) encoding the heterologous polypeptide, a linker nucleic acid sequence (iii) encoding an amino acid sequence that is specifically cleavable by enzymatic or chemical means; and d) contacting the lipid phase with said enzymatic or chemical means such that said heterologous polypeptide is released from the fusion polypeptide.
- 48. The method according to claim 47 wherein said linker nucleic acid sequence encodes an amino acid sequence that is recognizable by the proteolytic action of an enzyme selected from the group consisting of thrombin, factor Xa, collagenase, chymosin, clostrapain and viral protease.
- 49. The method according to claim 47 wherein said enzymatic means comprises an enzyme that is immobilized.
- 50. The method according to claim 49 wherein said enzyme is immobilized by attachment to an oil body protein that is associated with an oil body.
- 51. The method according to claim 42 wherein said recombinant polypeptide is an enzyme.
- 52. The method according to claim 51 wherein said recombinant polypeptide is an enzyme that retains its enzymatic properties while part of the fusion polypeptide is associated with the oil body.
- 53. A method of preparing an enzyme in a host cell in association with an oil body and releasing said enzyme from the oil body, said method comprising:
a) transforming a host cell with a chimeric nucleic acid sequence comprising:
1) a first nucleic acid sequence capable of regulating the transcription of 2) a second nucleic acid sequence, wherein said second sequence encodes a fusion polypeptide and comprises (i) a nucleic acid sequence encoding a sufficient portion of an oil body protein gene to provide targeting of the fusion polypeptide to an oil body; (ii) a nucleic acid sequence encoding an enzyme and (iii) a linker nucleic acid sequence located between said nucleic acid sequence (i) encoding the oil body and said nucleic acid sequence (ii) encoding the enzyme and encoding an amino acid sequence that is cleavable by the enzyme encoded by the nucleic acid sequence (ii); and 3) a third nucleic acid sequence encoding a termination region functional in said host cell b) growing the host cell to produce the fusion polypeptide under conditions such that enzyme is not active; c) recovering the oil bodies containing the fusion polypeptide; and d) altering the environment of the oil bodies such that the enzyme is activated and cleaves itself from the fusion polypeptide.
- 54. The method according to claim 53 wherein said enzyme is activated by lowering the pH or altering the temperature of the oil body environment.
- 55. The method according to claim 42 wherein said heterologous polypeptide is selected from the group consisting of antibodies, glycanases, hormones, proteases, protease inhibitors and seed storage proteins.
- 56. The method according to claim 42 wherein said heterologous polypeptide is selected from the group consisting of a thrombin inhibitor, hirudin, an interleuken, chymosin, cystatin, xylanase, carp growth hormone, zein, an antibody and a collagenase.
- 57. The method according to claim 42 wherein said host cell is an insect or animal cell.
- 58. A method according to claim 42 wherein said oil body protein gene is from a plant.
- 59. A method according to claim 58 wherein said oil body protein gene is an oleosin or a caleosin.
- 60. A method for the expression of a heterologous polypeptide by a host cell said method comprising:
a) generating by homologous recombination into a host cell a chimeric nucleic acid sequence comprising:
1) a first nucleic acid sequence capable of regulating transcription in said host cell 2) a second nucleic acid sequence, wherein said second sequence encodes a fusion polypeptide and comprises (i) a nucleic acid sequence encoding a sufficient amount of an oil body protein gene to provide targeting of the fusion polypeptide to a lipid phase, linked in reading frame to (ii) a nucleic acid sequence encoding the heterologous polypeptide; and 3) a third nucleic acid sequence encoding a termination region functional in the host cell; and b) growing said host cell to produce the heterologous polypeptide.
- 61. A chimeric nucleic acid sequence, capable of being expressed in association with an oil body of a host cell comprising:
1) a first nucleic acid sequence capable of regulating the transcription in said host cell of 2) a second nucleic acid sequence, wherein said second sequence encodes a fusion polypeptide and comprises (i) a nucleic acid sequence encoding a sufficient portion of an oil body protein gene to provide targeting of the fusion polypeptide to a lipid phase linked in reading frame to (ii) a nucleic acid sequence encoding the heterologous polypeptide; and 3) a third nucleic acid sequence encoding a termination region functional in the host cell.
- 62. The chimeric nucleic acid sequence according to claim 61 wherein said nucleic acid sequence (ii) encodes an enzyme.
- 63. The chimeric nucleic acid sequence according to claim 61 further including (iii) a linker nucleic acid sequence encoding an amino acid sequence that is specifically cleavable by enzymatic means wherein said linker nucleic acid sequence (iii) is located between said (i) nucleic acid sequence encoding the oil body protein and said (ii) nucleic acid sequence encoding the heterologous polypeptide.
- 64. The chimeric nucleic acid according to claim 63 wherein said linker nucleic acid sequence (iii) encodes a cleavage site for an enzyme selected from the group consisting of thrombin, factor Xa, collagenase chymosin and viral protease.
- 65. A chimeric nucleic acid sequence according to claim 61 wherein said oil body protein gene is from a plant.
- 66. A chimeric nucleic acid sequence according to claim 61 wherein said oil body protein gene is an oleosin or a caleosin.
- 67. An expression cassette comprising a chimeric nucleic acid sequence according to claim 61.
- 68. An animal transformed with a chimeric nucleic acid sequence according to claim 61.
- 69. A fusion polypeptide encoded for by a chimeric nucleic acid sequence comprising (i) a nucleic acid sequence encoding a sufficient portion of an oil body protein gene to provide targeting of the fusion polypeptide to a lipid phase and (ii) a nucleic acid sequence encoding a heterologous polypeptide.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of U.S. Ser. No. 09/210,843 that was filed Dec. 15, 1998, which is a continuation-in-part of U.S. Ser. No. 08/846,021 that was filed Apr. 25, 1997 (now U.S. Pat. No. 5,948,682), which is a continuation-in-part of U.S. Ser. No. 08/366,783 that was filed on Dec. 30, 1994 (now U.S. Pat. No. 5,650,554), which is a continuation-in-part of U.S. Ser. No. 08/142,418 that was filed Nov. 16, 1993 (now abandoned), which is a continuation-in-part of U.S. Ser. No. 07/659,835 that was filed on Feb. 22, 1991 (now abandoned), all of which are incorporated by reference in their entirety.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09893525 |
Jun 2001 |
US |
Child |
10763380 |
Jan 2004 |
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
09210843 |
Dec 1998 |
US |
Child |
09893525 |
Jun 2001 |
US |
Parent |
08846021 |
Apr 1997 |
US |
Child |
09210843 |
Dec 1998 |
US |
Parent |
08366783 |
Dec 1994 |
US |
Child |
08846021 |
Apr 1997 |
US |
Parent |
08142418 |
Nov 1993 |
US |
Child |
08366783 |
Dec 1994 |
US |
Parent |
07659835 |
Feb 1991 |
US |
Child |
08142418 |
Nov 1993 |
US |